Ipratropium Bromide Safety Profile

Established Adverse Effect Profile

Epistaxis (nasal bleeding) occurs in 9% of patients compared to 5% with placebo, according to the American College of Allergy, Asthma, and Immunology 1
Nasal dryness affects 5% of patients versus 1% with placebo, as reported by the American College of Allergy, Asthma, and Immunology 1
Blood-tinged mucus may occur but is mild and self-limiting, as noted by the American College of Allergy, Asthma, and Immunology 1

Ipratropium bromide is a quaternary ammonium compound that acts locally on muscarinic receptors in the airways and nasal mucosa, with poor systemic absorption, as described by the American Thoracic Society 1
The drug works by blocking cholinergically mediated secretions without affecting muscle tissue, according to the American Thoracic Society 1
Ipratropium bromide does not alter physiologic nasal functions, including sense of smell, ciliary beat frequency, or mucociliary clearance, as reported by the American Academy of Allergy, Asthma, and Immunology 2, 3

If a patient reports myalgia while using ipratropium bromide, consider alternative explanations such as concurrent viral illness, coexisting conditions like asthma or COPD exacerbations, or unrelated musculoskeletal conditions, as suggested by the American College of Chest Physicians 1, 2, 3
The extensive clinical experience with ipratropium bromide has not identified myalgia as an adverse effect, according to the American Academy of Allergy, Asthma, and Immunology 2